Calendar

The October 22 anchor of $132.65 is about 3.4% above the October 20 pre-release close of $128.27, so some of the favorable print is reflected in price; the available prices do not establish why shares moved. Verified post-print target increases are constructive, but the earnings surprise was modest and broader estimate-revision coverage remains incomplete. No usable social, options, short-interest or employee data were supplied; zero values in sentiment denote unavailable measures, not neutral observations. [Historical prices](https://stockscan.io/stocks/EWBC/price-history) [Morgan Stanley coverage](https://www.investing.com/news/analyst-ratings/morgan-stanley-raises-east-west-bancorp-stock-price-target-on-deposit-cost-improvement-93CH-4962504)

Company clinical updates support a constructive but provisional pipeline narrative. The supposed T+3 earnings event has not occurred: Q3 results are scheduled for October 28, so earnings surprise, subsequent analyst revisions and a results-linked market reaction cannot be measured. The $25.83 October 22 anchor alone does not establish a post-release price move. Zero-valued sentiment fields denote unavailable data, not neutral observations. [#PR-2026-10-21] [company announcement](https://ir.vikingtherapeutics.com/2026-10-21-Viking-Therapeutics-to-Report-Financial-Results-for-Third-Quarter-2026-on-October-28,-2026)

The Q3 company release materially strengthens the operating evidence, but the T+3 market response is unfavorable: VICR closed October 22 at $179.99, down 15.66% that day. The decline should not be attributed to a particular earnings concern without supporting coverage. Post-print analyst evidence is limited and mixed, including Roth MKM's lower target despite its retained Buy rating. Social, options, short-interest and employee measures were not supplied; zero entries above indicate unavailable data, not neutral readings. [Company release](https://vicorcorporation.gcs-web.com/node/17956); [price and analyst data](https://stockanalysis.com/stocks/vicr/forecast/).

The initial reaction held through October 22: UCB closed at $35.47 on the October 20 release date versus $33.78 on October 19, then at the $37.23 anchor on October 22—about 10.2% above the pre-release close. [Historical closes](https://chartexchange.com/symbol/nyse-ucb/historical/) News tone is constructive but the operating EPS result was in line with consensus, not an earnings beat. One verified post-print target increase from Stephens is supportive; broader estimate-revision evidence remains unavailable. Social, options, short-interest and employee-sentiment values are not supported by the packet and should not be interpreted as measured signals.

The earnings surprise and higher full-year EPS outlook improve the prior neutral thesis, consistent with the packet's positive directional prior and elevated thesis-change score. The market response was restrained: SYF closed down about 1.2% on October 20, then recovered to the packet's $75.09 October 22 anchor; that price path does not establish why investors traded. [Historical closes](https://stockanalysis.com/stocks/syf/history/). Barclays raised its target, but Evercore downgraded and lowered its target, so revisions are mixed rather than uniformly favorable. [Analyst revisions](https://www.benzinga.com/analyst-stock-ratings/price-target/26/10/62498895/these-analysts-revise-their-forecasts-on-synchrony-financial-after-q3-results). Social, options, short-interest and employee measures are unavailable; the zero fields are placeholders, not measured neutral readings.

The print and guidance are mixed-to-negative, but UAL closed October 21 at $101.67, about 4.0% above its $97.77 pre-release close, then reached the packet's $102 October 22 anchor. An initial premarket dip therefore did not persist. Post-print analyst revisions are mixed: Jefferies raised its target, while BMO and several other brokers cut theirs. The numerical sentiment fields above are unavailable-data placeholders, not measured neutral readings; social, options, short-interest and employee coverage was not supplied. [UAL price history](https://www.financecharts.com/stocks/UAL/summary/price) [Jefferies revision](https://www.tipranks.com/news/the-fly/united-airlines-price-target-raised-to-142-from-134-at-jefferies-thefly-news) [Broker revisions](https://www.marketscreener.com/news/united-airlines-forecasts-fourth-quarter-profit-below-estimates-as-fuel-costs-bite-ce785cd8dd81f725)